(2R)-1-(2-chloroethyl)-2-(methoxymethyl)pyrrolidine | 1039826-54-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2R)-1-(2-chloroethyl)-2-(methoxymethyl)pyrrolidine
• CAS: 1039826-54-4
• 化学式: C₈H₁₆ClNO
• 分子量: 177.674
• InChiKey: NBCHWTOPVNDSOH-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R)-1-(2-chloroethyl)-2-(methoxymethyl)pyrrolidine 、 5-溴吲唑 以 二甲基亚砜 为溶剂， 生成 (R)-5-bromo-1-(2-(2-(methoxymethyl)pyrrolidin-1-yl)ethyl)-1H-indazole
  参考文献：
  名称：

  5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists

  摘要：

  A new series of 5-(pyridinon-1-yl)indazoles with MCH-1 antagonist activity were synthesized. Potential cardiovascular risk for these compounds was assessed based upon their interaction with the hERG potassium channel in a mini-patch clamp assay. Selected compounds were studied in a 5-day diet-induced obese mouse model to evaluate their potential use as weight loss agents. Structural modification of the 5-(pyridinon-1-yl) indazoles to give 5-(furopyridinon-5-yl) indazoles provided compounds with enhanced pharmacokinetic properties and improved efficacy. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.039

文献信息

• 5-PYRIDINONE SUBSTITUTED INDAZOLES
  申请人：Guzzo Peter Robert

  公开号：US20100105679A1

  公开（公告）日：2010-04-29

  Various 5-substituted 1-substituted indazoles are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.

  本文介绍了各种5-取代的1-取代吲唑类化合物，以及含有这些化合物的药物组合物和使用这些化合物治疗疾病的方法。还介绍了其他实施例。
• US8268868B2
  申请人：——

  公开号：US8268868B2

  公开（公告）日：2012-09-18
• [EN] 5-PYRIDINONE SUBSTITUTED INDAZOLES<br/>[FR] INDAZOLES 5-PYRIDINONE SUBSTITUÉES
  申请人：AMR TECHNOLOGY INC

  公开号：WO2008086404A1

  公开（公告）日：2008-07-17

  [EN] Various 5-substituted 1-substituted indazoles are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.
  [FR] L'invention porte sur diverses indazoles 5-substituées 1-substituées, ainsi que sur des compositions pharmaceutiques contenant ces composés et sur des procédés permettant de traiter des maladies à l'aide desdits composés. L'invention concerne également d'autres modes de réalisation.
• 5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists
  作者：Matthew D. Surman、Emily E. Freeman、James F. Grabowski、Mark Hadden、Alan J. Henderson、Guowei Jiang、Xiaowu (May) Jiang、Michele Luche、Yuri Khmelnitsky、Steven Vickers、Jean Viggers、Sharon Cheetham、Peter R. Guzzo

  DOI：10.1016/j.bmcl.2010.09.039

  日期：2010.12

  A new series of 5-(pyridinon-1-yl)indazoles with MCH-1 antagonist activity were synthesized. Potential cardiovascular risk for these compounds was assessed based upon their interaction with the hERG potassium channel in a mini-patch clamp assay. Selected compounds were studied in a 5-day diet-induced obese mouse model to evaluate their potential use as weight loss agents. Structural modification of the 5-(pyridinon-1-yl) indazoles to give 5-(furopyridinon-5-yl) indazoles provided compounds with enhanced pharmacokinetic properties and improved efficacy. (C) 2010 Elsevier Ltd. All rights reserved.